Table 1.
Selected clinical trials targeting the p53 pathway in solid cancers.
| Class | Drugs | Phase | Tumor Types | ClinicalTrials.gov |
|---|---|---|---|---|
| p53 activator | APR-246 + Pembrolizumab | 1/2 | Solid Cancers | NCT04383938 |
| Wee1 inhibitor | AZD1775 | 1 | Solid Cancers |
NCT01748825 NCT04462952 NCT02482311 |
| ATR inhibitor | AZD6738 + Durvalumab | 2 | Bile Duct Cancer | NCT04298008 |
| MDM2 inhibitor | HDM201 | 1 | WT-p53 Solid Cancers | NCT02143635 |
| Idasanutlin | 1 | Solid Cancers | NCT03362723 | |
| MDM2/MDMX Inhibitor | ALRN-6924 + Paclitaxel | 1 | WT-p53 Solid Cancers | NCT03725436 |
| ALRN-6924 | 1 | WT-p53 Pediatric Cancer | NCT03654716 |